Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Common Equity (2016 - 2025)

Iradimed (IRMD) has disclosed Common Equity for 13 consecutive years, with $98.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 17.88% to $98.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $98.4 million, a 17.88% increase, with the full-year FY2024 number at $86.8 million, up 21.56% from a year prior.
  • Common Equity was $98.4 million for Q3 2025 at Iradimed, up from $94.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $98.4 million in Q3 2025 to a low of $62.5 million in Q1 2022.
  • A 5-year average of $75.2 million and a median of $72.2 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: dropped 3.06% in 2023, then rose 21.56% in 2024.
  • Iradimed's Common Equity stood at $72.2 million in 2021, then grew by 2.08% to $73.7 million in 2022, then decreased by 3.06% to $71.4 million in 2023, then rose by 21.56% to $86.8 million in 2024, then increased by 13.28% to $98.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Common Equity are $98.4 million (Q3 2025), $94.3 million (Q2 2025), and $90.1 million (Q1 2025).